Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases (Drugs, (2020), 80, 2, (99-113), 10.1007/s40265-020-01256-5)

Ho Ung Kim, Rieke Alten, Luisa Avedano, Axel Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M. Irving, Jørgen Jahnsen, Péter L. Lakatos, Jong Hyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven Simoens, Rene Westhovens, Silvio Danese, Ji Hoon Jeong

Research output: Comment/debate

Abstract

The affiliation of the corresponding author Silvio Danese, which currently reads.

Original languageEnglish
Pages (from-to)1039-1040
Number of pages2
JournalDrugs
Volume80
Issue number10
DOIs
Publication statusPublished - júl. 1 2020

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases (Drugs, (2020), 80, 2, (99-113), 10.1007/s40265-020-01256-5)'. Together they form a unique fingerprint.

  • Cite this

    Kim, H. U., Alten, R., Avedano, L., Dignass, A., Gomollón, F., Greveson, K., Halfvarson, J., Irving, P. M., Jahnsen, J., Lakatos, P. L., Lee, J. H., Makri, S., Parker, B., Peyrin-Biroulet, L., Schreiber, S., Simoens, S., Westhovens, R., Danese, S., & Jeong, J. H. (2020). Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases (Drugs, (2020), 80, 2, (99-113), 10.1007/s40265-020-01256-5). Drugs, 80(10), 1039-1040. https://doi.org/10.1007/s40265-020-01333-9